- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03755362
Dental Carotid Cognitive Study
Treatment of Periodontitis to Prevent Dementia in Older Adults With Asymptomatic Carotid Artery Stenosis and Mild Cognitive Impairment
Study Overview
Status
Intervention / Treatment
Detailed Description
Periodontal Disease (PD) is present in 60+% of adults >65 years and is associated with tobacco smoking, diabetes, and atherosclerosis that worsen inflammation, comorbidities common in older people with mild to moderate cognitive impairment (MCI). Older MCI patients are prone to poor oral hygiene and dental health, which if untreated worsens inflammation-mediated brain and nervous system function, and accelerates progression to dementia. Asymptomatic carotid artery stenosis (ACAS) is often a silent disease detected in only ~10% of older adults, and may have a strong association with MCI. This study examines the effects of intensive therapy for periodontitis on cognition in high-risk older people with ACAS. Results could highlight PD as a readily modifiable risk factor for dementia.
This pilot study examines the hypothesis that intensive treatment of PD (IPT) in older people with MCI and ACAS will attenuate their cognitive decline by reducing oral microbial-mediated inflammation and improving cerebrovascular endothelial function that contribute to neurodegeneration-associated dementia.
The aims are to determine the effects of intensive compared to control PD treatment (randomized: IPT vs. CPT) in 60 MCI subjects with ACAS and PD on 1) Cognitive function (Primary Outcome) and quality of life (Secondary Outcome), and 2) The potential mechanisms mediating these effects
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland - Administrative Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age equal to or greater than 65 years.
- Body Mass Index 18-35 kg/m2
- Mild to moderate periodontitis
- Mild to moderate cognitive impairment on Montreal Cognitive Assessment (MoCA) -range greater than or equal to 17 and less than or equal to 26 (i.e., range from 17-26).
- Detectable carotid plaque and carotid artery stenosis <70% as diagnosed by doppler ultrasound.
- Able to perform prescribed dental hygiene and travel to medical center as required to participate in the study.
Exclusion Criteria:
- Inability to provide informed consent.
- Subjects with inability to perform cognitive and other research testing
- Prior stroke, depression (CESD >16), neurologic or psychiatric disease that would affect cognitive testing, participation, and compliance to the research study.
- Subjects requiring chronic treatment with systemic corticosteroids or other systemic immunosuppressive drugs or drugs that would affect the dental treatments in the protocol are excluded.
- Subjects requiring essential dental care (e.g., treatment for grossly decayed teeth, broken teeth, dental abscesses, peri-apical infections, other dental infections).
- Inability to perform FDG-PET due to renal disease (eGFR <30 mL/min/1.75m2).
- Receiving anticoagulant therapy (Warfarin) with an INR greater than 3.3 at time of dental treatment or with a bleeding disorder, or other diseases that may interfere with dental therapy.
- Subjects with medical conditions that the clinicians feel would limit their ability to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Standard treatment (control)
Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
|
Dental evaluation at baseline, 3, 6, and 9 months.
|
EXPERIMENTAL: Intensive Treatment
Dental evaluation at baseline, 3, 6, and 9 months.
Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction.
Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth.
Additional evaluations and therapy at 2 months or as needed based on therapeutic response.
If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled.
Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
|
Dental evaluation at baseline, 3, 6, and 9 months.
Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction.
Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth.
Additional evaluations and therapy at 2 months or as needed based on therapeutic response.
If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled.
Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in performance on Montreal Cognitive Assessment (MoCA)
Time Frame: 1 year
|
The Montreal Cognitive Assessment (MoCA) is 30 item screening tool used to detect cognitive impairment.
Score: 30 points (maximum), 0 points (minimum).
Higher scores indicate better cognitive function.
Differences in rate of change of MoCA score in those on intensive treatment for periodontitis and those receiving standard care.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of oral bacteria in saliva and dental plaque samples
Time Frame: 1 year
|
Dental plaque and saliva samples will be analyzed for differences in species of oral microbial biology between those on standard care compared to those on intensive treatment for periodontitis.
Oral microbiome will be characterized using molecular genetic methods.
|
1 year
|
Presence of bacteria in stool samples
Time Frame: 1 year
|
Stool samples will be analyzed for differences in species of oral microbial biology between those on standard care compared to those on intensive treatment for periodontitis.
Stool microbiome will be characterized using molecular genetic methods.
|
1 year
|
Systemic inflammation
Time Frame: 1 year
|
Differences in inflammatory markers such as Interleukin 6 (IL-6) and tumor necrosis factor (TNF) alpha found in blood samples in those on standard care compared to those on intensive treatment for periodontitis.
|
1 year
|
Change from baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR)
Time Frame: 1 year
|
Brain metabolic activity or glucose metabolism will be determined using the FDG-PET scan by reporting results as SUVR and compared in those on intensive treatment for periodontitis and those receiving standard treatment for periodontitis.
|
1 year
|
Changes in performance on Wechsler Adult Intelligence Scale (WAIS)-III Digit Span subtest
Time Frame: 1 year
|
Change in Digit Span score as a measure of working memory in those on standard care compared to those on intensive treatment for periodontitis.
Raw score: 0-30, t score 19-77
|
1 year
|
Changes in performance on Hopkins Verbal Learning Test
Time Frame: 1 year
|
Change in Hopkins Verbal Learning test score in those on standard care compared to those on intensive treatment for periodontitis.
Total raw score: 0 (minimum)-36 (maximum), t score 19-77.
Higher scores indicate higher functioning.
|
1 year
|
Changes in performance on Brief Visuospatial Memory test
Time Frame: 1 year
|
Change in Brief Visuospatial Memory test score in those on standard care compared to those on intensive treatment for periodontitis.
Total raw score : 0 (minimum)-36 (maximum), t score 19-77.
Higher scores indicate higher functioning.
|
1 year
|
Changes in performance on Trail Making Test (A+B)
Time Frame: 1 year
|
Change in Trail Making Test (A+B) score as a measure of visual attention and task switching in those on standard care compared to those on intensive treatment for periodontitis.
Range: 10-400 seconds; t score 19-77.
Lower times indicate higher functioning.
|
1 year
|
Changes in performance on Controlled Oral Word Association Test
Time Frame: 1 year
|
Change in Controlled Oral Word Association Test as a measure of verbal fluency score in those on standard care compared to those on intensive treatment for periodontitis.
Total raw score : 0 (minimum)-90 (maximum); t score 19-77.
Higher scores indicate higher functioning.
|
1 year
|
Changes in performance on Boston Naming Test
Time Frame: 1 year
|
Change in Boston Naming Test score as a measure of confrontational word retrieval in those on standard care compared to those on intensive treatment for periodontitis.
Total raw score : 0 (minimum)-60 (maximum); t score 19-77.
Higher scores indicate higher functioning.
|
1 year
|
Changes in performance on Modified Wisconsin Card Sorting Test
Time Frame: 1 year
|
Change in Modified Wisconsin Card Sorting Test score as a measure of abstract reasoning ability in those on standard care compared to those on intensive treatment for periodontitis.
Number of categories score : 0 (minimum)-6(maximum); t score 19-77.
Higher scores indicate higher functioning.
|
1 year
|
Changes in performance on Grooved Pegboard Test
Time Frame: 1 year
|
Change in Grooved Pegboard Test score as a measure of visual-motor coordination in those on standard care compared to those on intensive treatment for periodontitis.
Range: 10-500 seconds; t score 19-77.
Lower times indicate higher functioning.
|
1 year
|
Changes in Composite Cognitive Function Score
Time Frame: 1 year
|
Change in composite cognitive function in those on standard care compared to those on intensive treatment for periodontitis.
T scores (19-77) of individual neuropsychological tests will be averaged to compute composite scores.
Neuropsychological tests include: Digit span, Hopkins Verbal Learning Test, Brief Visuospatial Memory test, Trail Making Test (A+B), Controlled Oral Word Association Test, Grooved Pegboard Test, Boston Naming Test, Modified Wisconsin Card Sorting Test.
|
1 year
|
Collaborators and Investigators
Investigators
- Study Director: Kimberlly Nordstrom, CCRC, University of Maryland, College Park
Publications and helpful links
General Publications
- Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.
- Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2012 Jan 4;87(1):10-20. doi: 10.1016/j.brainresbull.2011.10.004. Epub 2011 Oct 18.
- Leszek J, Barreto GE, Gasiorowski K, Koutsouraki E, Avila-Rodrigues M, Aliev G. Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System. CNS Neurol Disord Drug Targets. 2016;15(3):329-36. doi: 10.2174/1871527315666160202125914.
- Miklossy J, McGeer PL. Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation. Aging (Albany NY). 2016 Apr;8(4):575-88. doi: 10.18632/aging.100921.
- Otomo-Corgel J, Pucher JJ, Rethman MP, Reynolds MA. State of the science: chronic periodontitis and systemic health. J Evid Based Dent Pract. 2012 Sep;12(3 Suppl):20-8. doi: 10.1016/S1532-3382(12)70006-4.
- Daulatzai MA. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. J Neurosci Res. 2017 Apr;95(4):943-972. doi: 10.1002/jnr.23777. Epub 2016 Jun 27.
- Teixeira FB, Saito MT, Matheus FC, Prediger RD, Yamada ES, Maia CSF, Lima RR. Periodontitis and Alzheimer's Disease: A Possible Comorbidity between Oral Chronic Inflammatory Condition and Neuroinflammation. Front Aging Neurosci. 2017 Oct 10;9:327. doi: 10.3389/fnagi.2017.00327. eCollection 2017.
- Fouad A, Mongodin E, Hittle L, et al. Microbiome analysis of oral and atheromatous plaques in atherosclerotic patients. In: IADR General Session and Exhibition. 2014
- Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL, Davies M, West NX, Allen SJ. 16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer's Post-Mortem Brain. Front Aging Neurosci. 2017 Jun 20;9:195. doi: 10.3389/fnagi.2017.00195. eCollection 2017.
- Caminiti SP, Ballarini T, Sala A, Cerami C, Presotto L, Santangelo R, Fallanca F, Vanoli EG, Gianolli L, Iannaccone S, Magnani G, Perani D; BIOMARKAPD Project. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Neuroimage Clin. 2018 Jan 28;18:167-177. doi: 10.1016/j.nicl.2018.01.019. eCollection 2018.
- Ide M, Harris M, Stevens A, Sussams R, Hopkins V, Culliford D, Fuller J, Ibbett P, Raybould R, Thomas R, Puenter U, Teeling J, Perry VH, Holmes C. Periodontitis and Cognitive Decline in Alzheimer's Disease. PLoS One. 2016 Mar 10;11(3):e0151081. doi: 10.1371/journal.pone.0151081. eCollection 2016.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arterial Occlusive Diseases
- Neurocognitive Disorders
- Stomatognathic Diseases
- Periodontal Diseases
- Mouth Diseases
- Pathological Conditions, Anatomical
- Carotid Artery Diseases
- Cognition Disorders
- Periodontitis
- Carotid Stenosis
- Cognitive Dysfunction
- Constriction, Pathologic
Other Study ID Numbers
- HP-00082777
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontitis
-
Azienda Socio Sanitaria Territoriale degli Spedali...Università degli Studi di FerraraCompletedPeriodontitis, Aggressive | Periodontitis, AdultItaly
-
Panineeya Mahavidyalaya Institute of Dental Sciences...Research Institute for Genetic and Human TherapyUnknownGeneralized Adult Periodontitis
-
Asem Mohammed Kamel AliCompletedMolar-incisor Pattern Grade C Periodontitis ( Localized Aggressive Periodontitis) | Generalized Grade C Periodontitis (Generalized Aggressive Periodontitis)Egypt
-
Columbia UniversityCompletedPeriodontal Diseases | Generalized Moderate Chronic Periodontitis | Generalized Severe Chronic PeriodontitisUnited States
-
Postgraduate Institute of Dental Sciences RohtakUnknownChronic Apical PeriodontitisIndia
-
Aga Khan UniversityCompletedChronic Apical PeriodontitisPakistan
-
University of SienaNot yet recruitingPeriodontitis, AdultItaly
-
Lithuanian University of Health SciencesCompleted
-
Louisiana State University Health Sciences Center...CompletedPeriodontitis, AdultUnited States
-
University of BergenCompletedPeriodontitis | Adult Periodontitis
Clinical Trials on Standard Treatment
-
Paul CrawfordCompleted
-
Hospital Clinic of BarcelonaUnknown
-
Hospices Civils de LyonTerminatedAnal IncontinenceFrance
-
BaroPace Inc.JSS Medical Research Inc.RecruitingHypertension | Heart Failure With Preserved Ejection Fraction (HFpEF)India
-
Yale UniversityNational Institutes of Health (NIH)Completed
-
The University of Hong KongNot yet recruitingStroke | Small Vessel Cerebrovascular Disease
-
Pharmazz, Inc.CompletedHypovolemic ShockIndia
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingThoracic Cancer | Palliative Care | RadiotherapyItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingPelvic Cancer | Palliative Care | RadiotherapyItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingPalliative Care | Brain Metastases | RadiotherapyItaly